| Literature DB >> 34281454 |
Sheng Gao1,2, Xi Huang1,2, Yi Zhang1,2, Li Bao1, Xiaoyue Wang1, Meixia Zhang1,2.
Abstract
Diabetic retinopathy (DR) represents the most typical complication of type 2 diabetes mellitus and one of the most primary oculopathy causing blindness. However, the mechanism of DR remains unknown. RIPK1/RIPK3, as homologous serine/threonine kinases, are key elements in mediating necroptosis and may have functions in DR development. To clarify the relationship between DR and RIPK1/RIPK3, this study established a model of apoptosis using high-glucose induced RGCs, which were treated with 7.5, 19.5, and 35 mM D-glucose for 12, 24, and 48 h, respectively. Subsequently, the expression of RIPK1/RIPK3 was determined and the protective effect of necrostatin-1 on RGCs injury induced by high glucose was explored. The results demonstrated that the expression of RIPK1 and RIPK3 in the cells was increased markedly following 12 h treatment with 19.5 mM D-glucose. Additionally, following an addition of 100 μM necrostatin-1 in 19.5 mM D-glucose medium for RGCs treatment 12 h, the protein expression of RIPK1 and RIPK3 was decreased markedly, and the number of Nissl bodies in cells was increased substantially. The findings of the present study indicated that high glucose could induce the expression of RIPK1/RIPK3, and necrostatin-1 could effectively protect RGCs from D-glucose-induced cell necrosis.Entities:
Keywords: D-glucose; RGCs; RIPK1/RIPK3; diabetic retinopathy
Mesh:
Substances:
Year: 2021 PMID: 34281454 PMCID: PMC8806785 DOI: 10.1080/21655979.2021.1944456
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Figure 1.Isolation and identification of RGCs in mice. A, RGCs in mice under white light. B, Unstained cells were used as a blank internal reference to eliminate systematic errors. C, Positive rate of Thy1.2 cells by flow cytometry, the Thy1.2 antibody labeled treatment group. D, Statistical chart of the results by flow cytometry. The scale bar is 100 microns. ##, p < 0.01
Figure 2.Expression of RIPK1 and RIPK3 proteins in RGCs was promoted following D-glucose treatment. A, Protein expressions of RIPK1, p-RIPK1, RIPK3, and p-RIPK3 were detected by WB after treatment of 7.5 mM, 19.5 mM, and 35 mM D-glucose for 12, 24, and 48 h. B-E, Grayscale statistics
Figure 3.RIPK1 and RIPK3 were detected by immunofluorescence assay. Expression and distribution of RIPK1 and RIPK3 in cells were detected by immunofluorescence following treatment with 19.5 mM D-glucose at 12 h
Figure 4.Necrostatin-1 inhibited the expression of RIPK1 and RIPK3. A, Protein expression levels of RIPK1 and RIPK3 by WB. B, Number of Nissl bodies by Nissl staining. #, p < 0.05